Sio Gene Therapies Valuation
| SIOXDelisted Stock | USD 0.40 0.01 2.56% |
Sio Gene is overvalued. Sio Gene Therapies has a current Real Value of $0.35 per share. The regular price of the company is $0.4. Our model measures the value of Sio Gene Therapies from inspecting the company fundamentals such as Return On Equity of -0.47, shares outstanding of 73.98 M, and Shares Owned By Institutions of 26.82 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sio Gene's price fluctuation is very steady at this time. Calculation of the real value of Sio Gene Therapies is based on 3 months time horizon. Increasing Sio Gene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sio Gene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sio Stock. However, Sio Gene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.4 | Real 0.35 | Hype 0.4 | Naive 0.4 |
The intrinsic value of Sio Gene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sio Gene's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sio Gene Therapies helps investors to forecast how Sio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sio Gene more accurately as focusing exclusively on Sio Gene's fundamentals will not take into account other important factors: Sio Gene Total Value Analysis
Sio Gene Therapies is at this time estimated to have valuation of (23.36 M) with market capitalization of 30.63 M, debt of 2.36 M, and cash on hands of 54.77 M. The negative valuation of Sio Gene may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Sio Gene fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(23.36 M) | 30.63 M | 2.36 M | 54.77 M |
Sio Gene Asset Utilization
One of the ways to look at asset utilization of Sio is to check how much profit was generated for every dollar of assets it reports. Sio Gene Therapies has a negative utilization of assets of -0.24 %, losing $0.002434 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Sio Gene Therapies shows how discouraging it operates for each dollar spent on its assets.Sio Gene Ownership Allocation
Sio Gene Therapies shows a total of 73.98 Million outstanding shares. Sio Gene Therapies maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sio Gene Profitability Analysis
Net Loss for the year was (71.89 M) with profit before overhead, payroll, taxes, and interest of 0.About Sio Gene Valuation
Our relative valuation model uses a comparative analysis of Sio Gene. We calculate exposure to Sio Gene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sio Gene's related companies.Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York. Sio Gene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Sio Gene Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 73.2 M | |
| Retained Earnings | -863 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Sio Stock
If you are still planning to invest in Sio Gene Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sio Gene's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |